{"brief_title": "A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis", "brief_summary": "This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.", "condition": ["Osteoporosis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["placebo", "Denosumab"], "description": ["Placebo administered by subcutaneous injection", "Denosumab 60 mg administered by subcutaneous injection"], "arm_group_label": ["Placebo", "Denosumab 60 mg Q6M"], "other_name": ["AMG 162", "Prolia\u00ae"], "criteria": "Inclusion Criteria: - Women who are 60 to 90 years of age may be eligible to participate - Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5 Exclusion Criteria: - BMD T-Score at the hip or the spine of less than -4.0 - Patients with any severe or more than two moderate vertebral fractures on spinal x-ray at entry", "gender": "Female", "minimum_age": "60 Years", "maximum_age": "90 Years", "healthy_volunteers": "No", "keyword": "Postmenopausal Osteoporosis", "mesh_term": ["Osteoporosis", "Osteoporosis, Postmenopausal", "Denosumab"], "id": "NCT00089791"}